Yes, add Jardiance (empagliflozin) to metformin for this patient with an A1c of 8.3%.
You should add an SGLT-2 inhibitor like Jardiance (empagliflozin) to metformin when A1c remains above 7% despite adequate metformin dosing, as current guidelines strongly recommend SGLT-2 inhibitors as the preferred second-line agent due to their proven benefits in reducing all-cause mortality, major adverse cardiovascular events, chronic kidney disease progression, and heart failure hospitalizations 1.
Why SGLT-2 Inhibitors Are the Preferred Add-On
The 2024 American College of Physicians visual guideline provides the most recent high-quality evidence, giving a strong recommendation with high-certainty evidence to add an SGLT-2 inhibitor to metformin when glycemic control is inadequate 1. This supersedes older approaches that might have considered sulfonylureas or DPP-4 inhibitors.
The guideline explicitly states to use an SGLT-2 inhibitor to reduce the risk for all-cause mortality, MACE, progression of CKD, and hospitalization due to CHF 1. These mortality and morbidity benefits extend beyond simple glucose lowering, which is why SGLT-2 inhibitors are prioritized even in patients without established cardiovascular disease or kidney disease.
Expected Glycemic Benefit
With an A1c of 8.3%, adding empagliflozin should reduce A1c by approximately 0.6-0.8%, bringing this patient close to or below the 7-8% target range 2, 3. Multiple trials demonstrate:
- Empagliflozin 10 mg reduces A1c by approximately 0.6-0.7% when added to metformin 2
- Empagliflozin 25 mg reduces A1c by approximately 0.7-0.8% when added to metformin 2
- These reductions are sustained long-term, with 76-week data showing maintained efficacy 4
Dosing Recommendation
Start with empagliflozin 10 mg once daily, which can be increased to 25 mg once daily if additional glycemic control is needed 2. Both doses are effective, but starting at 10 mg allows assessment of tolerability before escalation.
Additional Benefits Beyond Glucose Control
Adding empagliflozin will provide:
- Weight loss: Expect 2-2.5 kg reduction over 24 weeks 2
- Blood pressure reduction: Systolic BP decreases by approximately 3-5 mmHg 2, 5
- Cardiovascular protection: Reduced risk of heart failure hospitalization and cardiovascular death 6, 1
- Renal protection: Slowed CKD progression 6, 1
Safety Considerations and Common Pitfalls
Hypoglycemia risk is very low when SGLT-2 inhibitors are added to metformin alone. Studies show confirmed hypoglycemia rates of only 1.4-1.8% with empagliflozin plus metformin versus 0.5% with placebo 2. This is a major advantage over sulfonylureas, which cause hypoglycemia in 24% of patients 7.
Key safety points:
- Genital mycotic infections occur in 3.7-4.7% of patients 2. Counsel on hygiene and early treatment.
- Urinary tract infections are slightly increased (5.1-5.6% vs 4.9% with placebo) 2
- Volume depletion: Ensure adequate hydration, especially in elderly patients or those on diuretics 8
- Ketoacidosis risk: Rare but serious. Educate patients to stop empagliflozin during acute illness, surgery, or prolonged fasting 8
- Check eGFR before starting: Empagliflozin is approved for use with eGFR ≥20 mL/min/1.73m² for glycemic control 8
Why Not Other Options
The 2024 ACP guideline strongly recommends against adding DPP-4 inhibitors to metformin due to lack of mortality/morbidity benefit 1. While empagliflozin was non-inferior to sitagliptin for glucose lowering 5, only SGLT-2 inhibitors provide the cardiovascular and renal protection that improves patient outcomes.
Sulfonylureas like glimepiride are inferior to SGLT-2 inhibitors for reducing all-cause mortality and morbidity, with a 12-fold higher hypoglycemia rate (24% vs 2%) 7. They should only be considered when cost is prohibitive and SGLT-2 inhibitors are not accessible 1.
Target A1c and Monitoring
Aim for an A1c between 7-8% in most adults with type 2 diabetes 1. With metformin 2000 mg daily plus empagliflozin, this patient should reach target within 12-24 weeks.
Self-monitoring of blood glucose may be unnecessary when using metformin plus an SGLT-2 inhibitor, as hypoglycemia risk is minimal 1. Check A1c in 3 months to assess response.
Cost Considerations
While no generic SGLT-2 inhibitors are currently available, discuss medication costs with the patient and explore patient assistance programs if needed 1. The mortality and morbidity benefits justify the expense when financially feasible, but if cost is truly prohibitive, consider GLP-1 agonists as an alternative (also no generic available) or, as a last resort, sulfonylureas with careful hypoglycemia counseling.